Sensorion SA
Research Sensorion SA (ALSEN) on Bullrun: market cap EUR 76.24M, P/E 0.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALSEN
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 76.24M
- P/E0.4
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 29.43M
- Free cash flow-EUR 28.04M
Valuation Snapshot
latest market cap is EUR 76.24M; P/E is 0.4.
Peer valuation comparison
Latest P/E is 0.36x versus a Healthcare sector median of 24.67x (98.5% below).
Latest P/E is 0.36x versus a France median of 14.07x (97.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 29.43M | -EUR 28.04M | n/a | -0.1 | EUR 47.46M | EUR 1.28M | EUR 44.48M |
| FY2024 | EUR 0 | -EUR 25.97M | -EUR 22.45M | n/a | -0.09 | EUR 66.77M | EUR 2.20M | EUR 72.14M |
| FY2023 | EUR 0 | -EUR 22.06M | -EUR 21.64M | n/a | -0.18 | EUR 36.97M | EUR 2.87M | EUR 33.28M |
| FY2022 | EUR 140.05K | -EUR 23.21M | -EUR 22.90M | n/a | -0.29 | EUR 26.20M | EUR 3.85M | EUR 21.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | EUR 76.24M | 0.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sensorion SA's market cap?
Sensorion SA's market capitalization is EUR 76.24M.
What is Sensorion SA's P/E ratio?
Sensorion SA's price-to-earnings (P/E) ratio is 0.4.
What does Sensorion SA do?
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies.